Beam Therapeutics Inc (NASDAQ: BEAM) on Monday, soared 3.13% from the previous trading day, before settling in for the closing price of $21.38. Within the past 52 weeks, BEAM’s price has moved between $16.95 and $49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 43297.50% over the last five years. The company achieved an average annual earnings per share of -212.06%. With a float of $67.88 million, this company’s outstanding shares have now reached $81.63 million.
The firm has a total of 436 workers. Let’s measure their productivity.
Beam Therapeutics Inc (BEAM) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Beam Therapeutics Inc is 16.88%, while institutional ownership is 78.29%. The most recent insider transaction that took place on Apr 02 ’24, was worth 504,851. In this transaction Chief Medical Officer of this company sold 16,530 shares at a rate of $30.54, taking the stock ownership to the 70,060 shares. Before that another transaction happened on Apr 01 ’24, when Company’s CEO sold 18,102 for $32.13, making the entire transaction worth $581,617. This insider now owns 1,058,343 shares in total.
Beam Therapeutics Inc (BEAM) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -212.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Beam Therapeutics Inc (BEAM) is currently performing well based on its current performance indicators. A quick ratio of 5.89 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.91, a number that is poised to hit -1.42 in the next quarter and is forecasted to reach -5.06 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Analysing the last 5-days average volume posted by the [Beam Therapeutics Inc, BEAM], we can find that recorded value of 1.28 million was lower than the volume posted last year of 1.44 million. As of the previous 9 days, the stock’s Stochastic %D was 15.55%. Additionally, its Average True Range was 1.54.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 4.22%, which indicates a significant decrease from 17.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 44.98% in the past 14 days, which was lower than the 80.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.82, while its 200-day Moving Average is $27.25. Now, the first resistance to watch is $22.65. This is followed by the second major resistance level at $23.24. The third major resistance level sits at $23.81. If the price goes on to break the first support level at $21.49, it is likely to go to the next support level at $20.92. Now, if the price goes above the second support level, the third support stands at $20.33.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
Market capitalization of the company is 1.80 billion based on 82,310K outstanding shares. Right now, sales total 377,710 K and income totals -132,530 K. The company made 316,190 K in profit during its latest quarter, and 142,800 K in sales during its previous quarter.
